The first patient in the MELD-ATG trial has been screened in UZ Leuven. The idea of this INNODIA trial is to see whether ATG will stop the immune system from attacking the insulin producing β cells in the pancreas. More news following soon.
![](/images/news/2020-11-25 First-sample-arriving-in ucam.jpg)
![](/images/news/2020-11-25 First-aliquod-arriving-in-ucam.jpg)
26. November 2020
The first patient in the MELD-ATG trial has been screened in UZ Leuven. The idea of this INNODIA trial is to see whether ATG will stop the immune system from attacking the insulin producing β cells in the pancreas. More news following soon.